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COMMENTARY Open Access
From sexless to sexy: Why it is time for
human genetics to consider and report
analyses of sex
Matthew S. Powers1, Phillip H. Smith2, Sherry A. McKee3 and Marissa A. Ehringer1*
Abstract
Science has come a long way with regard to the consideration of sex differences in clinical and preclinical research, but
one field remains behind the curve: human statistical genetics. The goal of this commentary is to raise awareness and
discussion about how to best consider and evaluate possible sex effects in the context of large-scale human genetic
studies. Over the course of this commentary, we reinforce the importance of interpreting genetic results in the context
of biological sex, establish evidence that sex differences are not being considered in human statistical genetics, and
discuss how best to conduct and report such analyses. Our recommendation is to run stratified analyses by sex no
matter the sample size or the result and report the findings. Summary statistics from stratified analyses are helpful for
meta-analyses, and patterns of sex-dependent associations may be hidden in a combined dataset. In the age of
declining sequencing costs, large consortia efforts, and a number of useful control samples, it is now time for the field
of human genetics to appropriately include sex in the design, analysis, and reporting of results.
Background
In order to increase scientific rigor and reproducibility,
Drs. Collins (Director, NIH) and Clayton (Director,
Office of Research on Women’s Health) spearheaded an
effort to require preclinical scientists to consider sex dif-
ferences in their research [1]. A similar policy addressing
the inclusion of women in clinical research has been in
effect since 1993 [2]. Researchers are now working
towards identifying how best to operationalize these
policy initiatives across disciplines and disorders (e.g.,
[3–6]). The goal of this commentary is to raise aware-
ness and discussion about how to best consider and
evaluate possible sex effects in the context of large-scale
human genetic studies. In particular, given the current
rapid decline in whole genome sequencing costs, the
relative affordability of high-throughput genotyping
arrays, the establishment of large publicly available data-
sets and ongoing efforts of international consortia, the
time is right to begin including sex as an important
variable of interest.
Over the course of this commentary, we hope to
accomplish four goals: (1) identify why sex differences
are important to consider in the context of genetics; (2)
establish evidence that sex differences are not being
considered in human genetics; (3) provide compelling
counter-arguments to the traditional reasons given for
not considering sex differences in genome-wide associ-
ation studies (GWAS); and (4) offer suggestions on how
to test for sex differences in analyses and why it is
important to include and report these analyses, no mat-
ter the result.
Sex differences in genetics
Many fields in biology under-report sex differences and
experiments that include this important variable are
unfortunately low. Conducting and reporting sex differ-
ences in clinical and preclinical research have increased
due to government policy, however, it remains an excep-
tion to the rule in science as a whole. One discipline,
human genetics, has escaped the attention of govern-
ment regulations and still largely ignores biological sex.
There are a number of reasonable explanations for not
including sex in human genetics studies (discussed later),
but evidence across all levels of biomedical research
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show that ignoring sex also ignores an important bio-
logical context created by our genes, and within which
our genes exist.
The most obvious difference between the sexes’ ge-
nomes is the presence of the Y-chromosome. Although
most of Y-chromosome research to date primarily
focuses on its role in sex determination and spermato-
genesis (fertility), the advancement of molecular genetic
tools has provided preliminary evidence that the Y-
chromosome is involved in more than just sex determin-
ation and fertility. For example, the Y-chromosome has
retained genes over evolution that are broadly expressed,
dosage-sensitive, and encode proteins involved in chroma-
tin modification, transcription, splicing, and translation.
While a thorough discussion of the role of the Y-
chromosome outside of the reproductive tract is be-
yond the scope of this commentary, we direct the
reader to a review by Hughes and Page [7] that provides
a compelling argument for why we should study the
role of the Y-chromosome in the genetics of disease.
Along with the presence/absence of the Y-chromosome,
males and females also differ in the number of X-
chromosomes present. Until recently, very little infor-
mation was generated about the X-chromosome’s
relationship to complex human disease because most
studies omitted it from analysis, or did the analysis in-
correctly [8]. Past reasons for this omission include lack
of coverage on genotyping chips, different number of
genes on the X-chromosome versus the autosomes, and
lack of statistical power to detect associations. With the
advances in genotyping technology, though, microar-
rays now include thousands of markers on the X-
chromosome compared to the arrays of old that include
only a few. This increase in amount and quality of X-
chromosomal data is beginning to uncover associations
between X-linked genes and conditions like auto-
immune disease [9], autism [10, 11], impaired cognitive
function [12], and even alcoholism [13]. Further, genes
on the X-chromosome are more likely to have sex-specific
expression compared to genes on the autosomes [14, 15],
which results from X-inactivation in females. However,
the copy of the X-chromosome that is inactivated differs
within each cell and some genes (~15%) on the second X-
chromosome avoid X-inactivation altogether, which can
lead to increased expression of the X-linked gene(s) in fe-
males compared to males [15]. Further, X-linked genes are
all fully expressed in males, making them more likely than
females to be influenced by X-linked genetic variations.
Chromosomal differences aside, males and females
differ remarkably with regards to the structure of their
genomes. For example, analysis of post-mortem human
brains show that around 2.5% of all genes are differentially
spliced and expressed between males and females [16],
suggesting that the regulatory genome differs between
sexes. Indeed, a number of studies across model species
(e.g., flies, rodents) show mRNA expression level differ-
ences that depend on sex (e.g., [17–19]). To put this in
perspective, unrelated human males share 99.9% of their
genomes while unrelated males and females share only
about 98.5% [16] (although this estimate is somewhat con-
troversial). This could mean that the genome of a human
male may be more similar to the genome of a male chim-
panzee, sharing around 98.8% (e.g., [20, 21]) than between
human males’ and females’ genomes. Despite these differ-
ences in the shared genome between males and females,
sex differences in disease phenotype/genotype relation-
ships are often not directly studied, even though there are
many examples of diseases that differ in prevalence by sex.
Sex differences in gene expression patterns are import-
ant to highlight, as these differences can be due to
genetic regulatory machinery like enhancers, binding
sites for transcription factors, or sex steroid hormone
receptors that predominantly exist in the non-coding
(non-exonic) regions of the genome. Interestingly, these
non-coding regions often include disease-associated sin-
gle nucleotide polymorphisms (SNPs) (e.g., [22, 23]).
Differences in the regulatory genome between sexes and
the existence of disease-relevant SNPs in regulatory
regions support the likely possibility that bi-directional
relationships exist between genotype and phenotype that
can depend on sex. To add further complexity, these bi-
directional relationships can both exaggerate phenotypic
variation between sexes, but also minimize differences,
as is the case with genetic compensatory mechanisms
(e.g., X-inactivation) [24]. Thus, if the statistical associa-
tions that capture such relationships are opposite in
direction for female compared to male genomes, or sub-
stantially stronger for one sex compared to the other, a
composite association may mask important relation-
ships. Indeed, this has proven to be the case; a 2015
case/control candidate gene study of age-related macular
degeneration (AMD) provided the first evidence of a
disease association that is female-specific [25]. The
analysis uncovered a SNP within the DAPL1 gene,
rs17810398, which is associated with AMD at the
genome-wide significance level in females (p = 2.6 × 10
−8), but not in males (p = 0.382). rs17810398 had not
been previously identified as associated with AMD in
large GWAS. While the functional implications of this
sex-specific association between rs17810398 and AMD
risk are still unknown, a more recent study by the same
group identified another sex-specific locus related to
copy number variation in the complement component
4A gene, which had a strong protective effect in
females [26]. Results such as these highlight the cost of
not performing sex-specific analyses—that information
valuable to the health of both sexes may remain
undiscovered.
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The importance of considering sex in human genetic
studies is not just limited to the realm of uncovering
high-confidence associations between genotype and
phenotype that would be hidden when sex is not consid-
ered. Ignoring potential sex-specific association both
stalls scientific progress and can have even broader
consequences. For example, we know that in vivo
pharmacodynamics and pharmacokinetics can depend
on sex (e.g., [27–29]), ethnicity (e.g., [30]), and genotype,
but human geneticists often assess the impact of ethni-
city and not sex. Important theoretical (e.g., population
migration, natural selection, founder effect, etc.) and his-
torical (e.g., subtle differences in ethnicity between case
and control populations led to false positive findings)
reasons underscore why geneticists assess the impact of
ethnicity, but there are clear theoretical and evidence-
based justifications for why assessing biological sex is
important as well, as discussed above.
Another important reason for assessing and reporting
analyses of sex relates to the impact that genetic associ-
ation studies will have (and have had) on personalized
medicine. As pharmacogenetics and other therapeutic
approaches that are driven by individuals’ genotype be-
come more prominent in healthcare, the consequences
of not considering sex differences in treatment decisions
has the potential to be harmful to not only the patient,
but possibly the field of pharmacogenetics as a whole if
public confidence in the field is diminished. To highlight
potential consequences, we can consider an example of
neuropathic pain. Emerging reports indicate that females
with variants in the MC1R gene show analgesia to the
kappa-opioid drug pentazocine, but males with the same
variants do not [31]. Moreover, polymorphisms in the
OPRM1 gene are associated with pressure-related pain
sensitivity in men but not in women [32]. Clearly, these
sex-specific associations have implications for the effi-
cacy of treatment options, but given the extreme de-
pendence liability of opioid drugs, choosing a drug that
will not be effective for its intended use in certain geno-
types increases dependence liability while showing no
treatment efficacy. Sex differences in drug efficacy alone
should be enough to increase assessment and reporting
of sex effects, but potentially increasing a negative out-
come like drug dependence in one sex compared to the
other is obviously an important consideration.
Sex is not studied in human genetics
To gain insight into the proportion of human genetics
studies that include sex differences in their analyses,
literature searches were conducted using two search
engines: PubMed and Web of Science (note that we did
not curate or trim the search results in anyway).
PubMed was used because it is the standard search en-
gine in biomedical research, is human curated, and only
searches titles/abstracts/keywords. Web of Science, like
PubMed, is human curated and searches titles/abstracts/
keywords, but has the added benefit of sorting results by
the number of times an article is cited, allowing us to
focus on only high-impact articles (defined as an article
cited ≥100 times). Both searches were limited to human
subjects.
The first literature search aimed to retrieve all papers
that test for genetic associations, so the search terms were
“genome-wide association study” OR (“genome-wide”
AND “association”) OR “gwas” OR (“genome” AND “asso-
ciation”) OR (“exome” AND “association”) OR (“transcrip-
tome” AND “association”) AND “humans” and returned a
total of 32,779 results from PubMed, and 3039 from Web
of Science (with ≥100 citations). The second search aimed
to retrieve all genetic association publications that include
mention of sex differences and/or analyses of sex, and
therefore “sex difference” OR “by sex” OR “sex-specific”
were added. This search returned a total of 168 results
from PubMed (or 0.5% of all PubMed results) and 33 from
Web of Science (or 1% of results from the most cited arti-
cles in the field). In addition to limiting our above search
to “sex”-related terms, we repeated the search using the
terms “X-chromosome” and “Y-chromosome.” Inclusion
of the term “X-chromosome” yielded 195 articles from
PubMed (0.6%) and 18 from Web of Science with ≥100 ci-
tations (0.6%). Inclusion of the term “Y-chromosome”
yielded 63 articles from PubMed (0.19%) and 4 from Web
of Science with ≥100 citations (0.13%).
These search results are surprising; 1% of genetic asso-
ciation study publications in either PubMed or Web of
Science report anything related to sex differences in
their searchable text and an even smaller proportion
consider the sex chromosomes. The extremely low per-
centage of reported sex differences underscores the lack
of attention to this subject in human genetics, and high-
lights the need for future studies to not only include sex
as an important biological variable, but also report the
result within the searchable text (i.e., title/abstract/key-
word). To be fair, it is likely that sex differences are
considered more often than are being reported in the
literature. Unpublished results due to publication bias
remain an unaddressed problem in science, and this
ultimately contributes to wasted time and money. Not
reporting sex differences, even if null, presents the same
problem in that it restricts information that can be use-
ful for other scientists.
Why analyses of sex are often neglected in human
genetic studies
Both clinical and preclinical researchers are routinely re-
quired to consider sex differences, but human genetic
studies have largely considered sex only by regressing it
out of statistical models. Most studies that assess sex in
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any way just include it as a covariate in their analyses,
along with other relevant confounding variables (e.g.,
age). However, this approach does not directly assess
whether genetic effects are dependent on sex, but in-
stead provides a loose estimate of sex effects that may or
may not be examined more closely. In other words, sex
is often included as a control variable, and the variance
attributable to sex is not closely examined; it is essen-
tially parceled out and discarded.
Given the obvious importance of assessing sex in the
context of experimental results, why is it that sex differ-
ences are not more frequently studied in human genet-
ics? The likely answer is that a number of issues exist
when conducting statistical analyses on genetic data,
most of which are related to the size and complexity of
the datasets generated, as well as the wide variation in
selecting, defining, and measuring phenotypes. Because
of this size and complexity, researchers often use simple
statistical methods to uncover associations between
genotype and phenotype. For example, traditional
GWAS analyses typically examine >500,000 SNPs across
the genome, leading to demanding multiple testing
adjustment standards, setting the current standard for
genome-wide significance at p < 5 × 10−8 [33]. Such a
conservative p value threshold protects against detecting
false positives; however, some researchers have suggested
that the threshold is too conservative [34] and likely
leads to high rates of false negatives, which can stall pro-
gress much like publication bias. The inherent issues of
power and stringent p value thresholds has created a
culture aimed at increasing power at all costs, and one
of the casualties is little attention paid to sex.
The desire to maximize power also underlies the two
reasons routinely cited to justify controlling for sex in-
stead of directly assessing it. Not surprising, the main ra-
tionale is not enough statistical power to assess sex
differences because the sample size has to be split in
half. While it is often true that stratifying the data by sex
will reduce statistical power, it is also true that power to
detect an effect does not rely on sample size alone.
Stratifying analyses by sex can result in increased power
to detect significant genetic signals if the signals are
small (or null) in one sex and larger in the other, or if
large signals exist with opposite effects across sex [35].
In other words, if effect size is larger when split by sex
than when sex is combined, statistical power may actu-
ally increase. Thus, the rationale of “not enough statis-
tical power” becomes less justifiable.
The second reason used to justify controlling for sex is
that genotyping/sequencing costs are prohibitive, mak-
ing it extremely expensive to collect enough data to
reach the sample size necessary to uncover sex differ-
ences. While this argument was once valid, the price of
sequencing is rapidly declining, allowing for more
samples to be collected and the all-important statistical
power to increase. Further, large collaborative genetic
consortia are collecting genotype/phenotype data and
making it available to the scientific community at an
increasingly rapid pace. As these datasets continue to
expand, the availability of control/comparison samples
as well as replication samples grows, again increasing
statistical power. Declining sequencing cost combined
with the growth of consortia and data sharing efforts
should provide adequate sample sizes (at least control
group samples) to start assessing sex in human genetics.
Sex needs to be evaluated separately: best approach for
evaluation of sex in genetic studies is to stratify
With the recent directive from NIH to consider sex as a
variable of interest in preclinical studies, the best way to
approach it in human genetic studies is not yet clear.
Many investigators (and grant reviewers) still believe
strongly that reducing sample size by dividing the sam-
ple is not a good option. We hope this commentary will
serve as a starting point for these investigators to recon-
sider this stance, and that they will be involved in devel-
oping strategies to evaluate and report the impact of sex
in their work. Until best practices for considering sex in
human genetic studies are developed and refined, there
are some steps that can be taken now.
One strategy is to simply be less stringent in the rules
for power and multiple testing p value corrections, for
exploratory purposes. Typically, a significant treatment
× sex interaction is necessary to justify conducting a
follow-up analysis stratified by sex. However, uncovering
a significant interaction that passes correction for mul-
tiple testing in the realm of human genetics is difficult,
unless there is a very large sex effect on an association
between phenotype and genotype [36]. Thus, simply
conducting the analyses allowing for some flexibility
(less stringent with p values) often uncovers patterns in
the data, and patterns in data can be just as informative
as p values derived from association tests of single gen-
etic loci. Reconsider the story of rs17810398 within the
DAPL1 gene. Previous GWAS did not uncover an asso-
ciation between rs17810398 and age-related macular de-
generation, but when analyses were stratified by sex, the
association was highly significant for females (p = 2.6 ×
10−8) and not males (p = 0.382) [25]. Significant associa-
tions can be lost when combining male and female data
into one dataset.
Another strategy is to make use of publicly available
datasets, which are expanding every day. However, this
does not mean we need to wait for sample sizes to double
before asking questions about sex differences. The Psychi-
atric Genomics Consortium (PGC) currently has a sample
size of greater than 400,000 subjects with phenotypic in-
formation covering a wide range of psychiatric disorders
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[37]. Further, the PGC is committed to open sharing of
data, and because the NIH requires datasets to be pub-
lished along with manuscripts, recruiting enough individ-
uals’ genotype information is no longer an insurmountable
task, especially as data from “control” samples are growing
rapidly (e.g., 1000 genomes—[38]; Precision Medicine
Initiative®—[39]).
Even without access to the large publicly available da-
tabases, consistently conducting and reporting analysis
on sex in all genetic association experiments can be
beneficial to science in a number of ways. The first and
most obvious benefit is the possibility of detecting a
genome-wide significant result that depends on sex, even
while lacking a large enough sample size to reach
genome-wide significance in a combined male/female
dataset. As mentioned above, stratifying analyses by sex
can result in increased power to detect significant
genetic signals if the signals are small (or null) in one
sex and larger in the other, or if large signals exist with
opposite effects across sex [35]. Further, a difference in
variance (not means) between sexes is lost by a standard,
fixed effect regression term for sex; therefore conducting
analyses stratified by sex will improve power [40]. Finally,
estimates of genetic associations with non-significant
(genome-wide) p values can be useful to other researchers
who use meta-analytical techniques to synthesize data
across a large number of studies. By reporting the esti-
mates of association stratified by sex, they become usable
in meta-analyses, allowing for even more information to
be gleaned over time.
Another strategy is for journal editors to require the
reporting of sex statistics in order to publish, like many
of the other specific requirements for reporting results.
While helpful, requiring a separate section in all papers
for reporting sex differences may be too extreme, but a
few short sentences addressing the issue along with
supplementary tables is an option. Indeed, there is a
growing movement for journals to require the reporting
of results by sex. In 2012 the Institute of Medicine pub-
lished a report discussing the issue, and ultimately, the
report recommends (among other things) that journals
should require authors to present sex difference analyses
when the study design allows [41]. A number of high
impact journals (e.g., Lancet, Science, and Nature) have
developed policies outlining the inclusion and reporting
of sex differences (for a listing of journals and policies,
see [42]), and it is only a matter of time before the major
human genetics journals follow suit.
At this time, our recommendation is for all human
genetics experiments to conduct stratified analyses on
sex at all times, even without statistical justification in
the form of a sex × SNP interaction. Simply conducting
the analyses is not enough, though, as scientists will also
need to report that the analyses were done and what
they found, independent of the result. Furthermore, it is
important for investigators who do observe evidence for
sex differences to always include sex as a keyword in
their manuscript, which would allow for a more compre-
hensive results list when searching the literature for sex
differences.
Conclusion
The goal of this commentary is to raise awareness and
discussion about how to best consider and evaluate pos-
sible sex effects in the context of human genetic studies.
Herein, we presented arguments for why sex differences
are important to consider in the context of genetics,
established evidence that sex differences are not being
considered, and provided compelling counter-arguments
to the traditional arguments for not considering sex dif-
ferences in human genetics. Including sex in the design,
analysis, and reporting of results will improve the trans-
parency, rigor, and generalizability of genetic association
studies, accelerating scientific progress. The inclusion of
sex in genetic studies will ultimately improve our under-
standing of health and disease for both women and men.
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